Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nanog homeobox pseudogene 3 (NANOGP3) is classified as a processed pseudogene related to the Nanog homeobox transcription factor but does not code for a functional protein. NANOGP3 is one of several NANOG pseudogenes present in the human genome, thought to have arisen through retrotransposition events. Unlike the canonical NANOG (Nanog homeobox) gene, which encodes a key transcription factor essential for maintaining embryonic stem cell pluripotency and self-renewal, NANOGP3 lacks coding capacity and is not thought to have a regulatory or protein-coding function in normal cells. There is no evidence that NANOGP3 is directly implicated in disease biology, used as a biomarker, or targeted by drugs[3][5]. Key clarification: - NANOGP3 is distinct from the functional Nanog (NANOG) gene and its protein products, which are critical for stem cell biology and implicated in cancer[1][2][6]. - NANOGP3 is a pseudogene — a DNA sequence similar to a functional gene but without known protein-coding or regulatory function in humans[5]. - The presence of "NANOGP3" in a target list for drug discovery or biomarker investigation would generally constitute an error or misannotation, unless there is new evidence of its transcriptional or regulatory role, which current mainstream resources and primary literature do not support[5]. - No drugs target NANOGP3, nor is it known to participate in protein networks, signaling, or disease-modifying processes. Summary: NANOGP3 (Nanog homeobox pseudogene 3) is a non-functional pseudogene with no direct biological or therapeutic relevance; its inclusion as a target should be considered incorrect unless new data emerge. The functional, disease-relevant gene is "Nanog homeobox" (NANOG), a well-known homeobox transcription factor key to pluripotency and stem cell maintenance[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nanog homeobox pseudogene 3 (NANOGP3).